DSIJ Mindshare

Mukul Agrawal’s portfolio pharma stock to keep under radar as company announces consolidation of business in Europe; Details inside

The stock gave multibagger returns of over 200 per cent in just 1 year and a whopping 400 per cent in 2 years.

Kiran Shroff 1 136 Article rating: 3.3

The stock gave multibagger returns of over 200 per cent in just 1 year and a whopping 400 per cent in 2 years.

Amansa Holding buys 11,40,301 shares of small-cap multibagger pharma stock; company reduces debt and presents special situation opportunity!

Moreover, the company's announcement regarding the creation of OneSource in September 2023 marks a pivotal value enhancement opportunity for Strides shareholders

Karan Dsij 0 15904 Article rating: 3.8

Of significant note is the remarkable reduction in the company's debt-to-EBITDA ratio, which has undergone a substantial decline from 5.7x in FY'22 to 2.8x on an annualized quarterly basis, signaling a notable financial transformation. Despite surpassing guidance in debt reduction, the company continues to generate free cash flow

Mukul Agrawal bought 14,00,000 shares of small-cap multibagger pharmaceutical stock; FIIs also increased their holding in this stock!

Additionally, Foreign Institutional Investors/Foreign Portfolio Investors (FII/FPI) increased their holdings from 17.25 per cent to 19.45 per cent in the December quarter.

Karan Dsij 1 49737 Article rating: 3.9

The stock has surged nearly 107 per cent in the last year, transforming into a multibagger stock for investors.

RSS
DALAL STREET INVESTMENT JOURNAL - DEMOCRATIZING WEALTH CREATION

Principal Officer: Mr. Shashikant Singh,
Email: principalofficer@dsij.in
Tel: (+91)-20-66663800

Compliance Officer: Mr. Rajesh Padode
Email: complianceofficer@dsij.in
Tel: (+91)-20-66663800

Grievance Officer: Mr. Rajesh Padode
Email: service@dsij.in
Tel: (+91)-20-66663800

Corresponding SEBI regional/local office address- SEBI Bhavan BKC, Plot No.C4-A, 'G' Block, Bandra-Kurla Complex, Bandra (East), Mumbai - 400051, Maharashtra.
Tel: +91-22-26449000 / 40459000 | Fax : +91-22-26449019-22 / 40459019-22 | E-mail : sebi@sebi.gov.in | Toll Free Investor Helpline: 1800 22 7575 | SEBI SCORES | SMARTODR